We are live on ! Find out more
TVTX icon

Travere Therapeutics

319 hedge funds and large institutions have $5.98B invested in Travere Therapeutics in 2026 Q2 according to their latest regulatory filings, with 87 funds opening new positions, 122 increasing their positions, 86 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

211% more first-time investments, than exits

New positions opened: 87 | Existing positions closed: 28

175% more funds holding in top 10

Funds holding in top 10: 4 → 11 (+7)

55% more call options, than puts

Call options by funds: $77.8M | Put options by funds: $50.1M

42% more repeat investments, than reductions

Existing positions increased: 122 | Existing positions reduced: 86

30% more capital inflows, than outflows

Capital inflows: $885M | Capital outflows: $681M

22% more funds holding

Funds holding: 262 → 319 (+57)

4.22% more ownership

Funds ownership: 109.87% → 114.09% (+4.2%)

Holders
319
Holders Change
+57
Holders Change %
+21.76%
% of All Funds
3.8%
Holding in Top 10
11
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+175%
% of All Funds
0.13%
New
87
Increased
122
Reduced
86
Closed
28
Calls
$77.8​M
Puts
$50.1​M
Net Calls
+$27.7​M
Net Calls Change
+$500​K

TVTX Hedge Fund Activity: Q2 2026 in Review

319 of the 8,401 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2026, worth a combined $5.98B — up 99% from $3.01B a quarter earlier.

Buyers outnumbered sellers: 87 funds opened new TVTX positions and 28 closed out — a net gain of 59 holders — while 122 added to existing stakes and 86 trimmed.

The largest buyer was Bank of America, adding an estimated $143M. The largest seller was Fidelity Investments, cutting an estimated $172M.

  • 319 institutional investors held Travere Therapeutics (TVTX) as of Q2 2026, up from 262 in Q1 2026.
  • Funds reported $5.98B of Travere Therapeutics stock for Q2 2026, up 99% quarter-over-quarter.
  • 87 funds opened new Travere Therapeutics positions in Q2 2026 and 28 closed out, a net change of +59 holders.
  • The largest Travere Therapeutics buyer in Q2 2026 was Bank of America, an estimated $143M added.
  • The largest Travere Therapeutics seller in Q2 2026 was Fidelity Investments, an estimated $172M sold.

Based on aggregated 13F filings for Q2 2026.